基于结构的发现,用于喘治疗的强效和选择性小分子α5β1整蛋白抑制剂
Richard Beresis1, Aparna Sundaram2, Hyunil Jo1
1Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, United States.
ACS omega
|December 22, 2025
概括
选择性抑制整合素α5β1为喘提供了一个新的治疗策略. 强大的小分子抑制剂,通过吸入输送,显示减轻气道光滑肌张力和收窄的承诺.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 整体素α5β1对于气道光滑肌 (ASM) 中的纤维素结合至关重要.
- 调节α5β1可以减少喘模型中的呼吸道狭窄.
- 现有的α5β1抑制剂缺乏用于吸入性喘治疗的最佳特性.
研究的目的:
- 开发强效和选择性α5β1抑制剂用于吸入性喘治疗.
- 为了确定一种具有有利的药理动力学性质的化合物,用于每日一次剂量.
主要方法:
- 基于结构的设计和小分子的顺序优化.
- 在体外对各种整合素进行细胞功效和选择性测定.
- 在吸入后在动物中进行的体内药理动力学研究.
主要成果:
- 确定了一系列强大的α5β1抑制剂.
- 化合物65表现出亚纳米细胞功效和高选择性.
- 化合物65在吸入后显示出有利的动物药理动力学.
结论:
- 通过吸入选择性α5β1抑制是一种可行的喘治疗方法.
- 化合物65具有作为每天吸入一次的喘治疗的潜力.
- 通过α5β1抑制剂破坏细胞连接,可以降低ASM的紧张.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
Antiasthma Drugs: Muscarinic Receptor Antagonists
1.6K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.6K
Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K


